Skip to main content
OpenTrials
Completed

NCT Number: NCT05089968

Ventilation Associated Pneumonia and Covid-19

In December 2019, a new pandemic emerged, the COVID-19 disease caused by a SARS-Cov-2 virus. One of the most common symptoms of COVID-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation. Ventilator-associated pneumonia (VAP) is a risk of this assistance. Since the beginning of the pandemic, Standard of care have evolved with new data. The prevalence of these VAPs seems significantly higher in the population of patients with ARDS COVID-19 (40-50%) and their ecology seems to have evolved over time, particularly in terms of bacterial resistance. Investigators want to describe and compare this evolution of bacterial and fungal ecology as well as identify potential risk factors that may be associated with these changes in ecology during different waves.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

SARS-CoV2 Infection ARDS Acute Lung Injury COVID-19 Coronaviridae Infections Coronavirus Infections Cross Infection Disease Attributes Healthcare-Associated Pneumonia Iatrogenic Disease Infections Lung Diseases Lung Injury Nidovirales Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Ventilator-Associated Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Ventilator Associated Pneumonia Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Nîmes - Hôpital Universitaire Carémeau

Nîmes, 30029, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years
  • Positive SARS-Cov-2 polymerase chain reaction (PCR)
  • healthcare associated pneumonia

Exclusion criteria

Patient opposition to participate to the study

Treatment and study plan

Primary outcomes

  1. VAP ecological difference between the first and second waves of COVID

    Time frame: January 2020 to January 2021

    Proportion of patients admitted to critical care with documented multidrug-resistant bacteria (MDR) VAP in Covid-19 wave 1 and 2

Secondary outcomes

  1. proportion of fungal co-infections

    Time frame: January 2020 to January 2021

    Comparison of the proportion of patients with a fungal infection during the 1st and 2nd wave

  2. duration of mechanical ventilation

    Time frame: Day 28

    Number of days under mechanical ventilations

  3. number of days of organ failure

    Time frame: Day 28

    number of days between first organ failure and no organ failure (discharge from intensive care)

  4. Mortality

    Time frame: Day 28

    proportion of patients deceased at day 28

  5. proportion of patients treated with corticosteroid therapy

    Time frame: Day 28

    proportion of patients treated with corticosteroid therapy

  6. probabilistic antibiotic therapy at admission

    Time frame: Day 1

    probabilistic antibiotic therapy prescribed at admission

  7. antiviral treatment

    Time frame: Day 28

    proportion of patients treated with antiviral treatment

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Official study title

Ventilator-associated Pneumonia Ecology Comparison in a French ICU Center NIMES Between First and Second Wave of COVID-19 : a Retrospective Monocentric Descriptive Study

Acronym: ECOLCOVID

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Oct 22, 2021
Registry last updated
Oct 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.